At the recent IMPAKT Breast Cancer Conference, 2 – 4th May, Brussels, ecancer´s Peter Goodwin talks to Ana Vivancos about her pioneering research in cancer genomics and work contributing to improved phase I clinical studies and best therapies for patients.
Related Posts
Novel Akt inhibitor ipatasertib evidenced as a promising contender for therapy against solid tumors
Powerful downmodulation of Akt signaling with ipatasertib proves effective and tolerable in subgroup of patients who have developed resistance to…
01 Dec 2016
MoTriColor launches as a pan-European project aimed at the development of novel therapies for patients with advanced colorectal cancer
Receiving 6 M EUR in funding from the European Commission´s Horizon 2020 – the biggest EU Research and Innovation Programme,…
17 Nov 2015
Calling Young Scientists: deadline extended to 04 August to apply for EurocanPlatform´s Translational Cancer Research Course, 20 – 24 October 2014, Portugal
Aimed at exploring all aspects of the translational research continuum, from early detection through treatment to survivorship, this special 5-day…
10 Jul 2014
Vall d’Hebron successfully treats pregnant women with breast cancer
Vall d’Hebron successfully treats pregnant women with breast cancer • In 2006, the Breast Cancer Unit at the Vall d’Hebron…
16 Oct 2012
VHIO on the ground and delivering data at San Antonio Breast Cancer Symposium 2016
Now in its 39th annual edition, the San Antonio Breast Cancer Symposium (SABCS) is the world´s largest, multidisciplinary breast cancer…
08 Dec 2016
In The Lancet: Combining 2 anti-HER2 drugs may provide better preoperative breast cancer treatment
Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent.
18 Jan 2012
VHIO collaborates in European, multi-center study aimed at reducing side-effects of radiotherapy
Supported by the European Commission´s 7th Framework Programme of Research and Development, and coordinated by Catharine West, University of Manchester,…
13 Jan 2014
BIB launches portal to promote Catalan bioinformatics platform
Bioinformatics Barcelona (BIB), launched in 2014, constitutes a regionally-based multi-center bioinformatics platform as part of a joint initiative of the…
15 Jun 2016
Study describes phenomenon of resistance to novel therapy for advanced lung cancer
• Resistance to targeted therapies for lung cancer, the most common cancer worldwide, represents one of the major limitations in…
05 May 2015
Dr. José Baselga wins the "Physician of the Year” award from ABC Salud
The prize-giving ceremony was held on Thursday 7 April at the head office of the ABC newspaper in Madrid.
Dr. José Baselga, one of Spain’s most prestigious international oncologists and a key figure in the research and treatment of breast cancer, has been distinguished as “Physician of the Year”. This first edition of the ABC Health Awards recognises the outstanding work of medical professionals and institutions in the public and private health sectors.
11 Apr 2011
In celebration of improved outcomes for cancer patients driven by science: 24 September marks World Cancer Research Day
Established in 2016 by the Spanish Association against Cancer (AECC) and officially promoted in collaboration with leading organizations and societies*,…
19 Sep 2017
Immediate Call for Oustanding Principal Investigators in Basic/Translational Cancer Research & Immunology
The Vall d´Hebron Institute of Oncology (VHIO), invites immediate applications from outstanding individuals to establish and maintain energetic, independent and…
30 Dec 2013
Discovery of mechanisms predicting response to new treatments in colon cancer
The Vall d’Hebron Institute of Oncology (VHIO) identifies biomarkers that predict resistance to treatment which will enable a better selection of patients who stand to benefit as well as avoid the administration of ineffective medicines.
These findings identify experimental drugs to overcome resistance and open new therapeutic avenues in combinatorial treatment.
20 May 2012
Nature Reviews Cancer Viewpoint: Drugging the ´undruggable´ cancer targets
In a Nature Reviews Cancer Viewpoint article published online this week, four leading experts – Chi V. Dang, E. Premkumar…
26 Jun 2017
Members of the EC´s Research, Innovation, and Science Policy Experts high level group issue latest policy brief towards 2030
As part of a recently published policy brief entitled A Mission-oriented Approach to Cancer in Europe: A Joint Mission/ Vision…
16 Oct 2017
